Abstract
As noted by Gökbuget and colleagues,[1][1] licensing agencies increasingly depend on the results of single arm phase II trials.[2][2] As attention focuses on small, molecularly defined, patient subsets, urgent clinical need, and eagerness to test scientifically compelling targeted agents encourage

This publication has 10 references indexed in Scilit: